Skip to content

Practical RCT Study on Prevention and Treatment of Traditional Chinese Medicine for COPD Based on Disease Process Management

Practical RCT Study on Prevention and Treatment of Traditional Chinese Medicine for COPD Based on Disease Process Management

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010972
Enrollment
Unknown
Registered
2017-03-23
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Test group:Traditional Chinese medicine granules

Sponsors

Tianjin Binhai New Area Hospital of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) patients who meet the diagnostic criteria for COPD; (2) the degree of disease belonging to the I, II level of stable patients; (3) aged 40 to 80 years old; (4) clinical studies that did not participate in other interventions for the first three months; (5) voluntarily receive treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) acute exacerbation of COPD patients; (2) the degree of disease belongs to III, IV grade COPD patients; (3) pregnant and lactating women; (4) unconsciousness, dementia, all kinds of mental illness; (5) severe cardiac insufficiency and hemodynamic instability; (6) combined with bronchiectasis, bronchial asthma, pulmonary tuberculosis, bronchiolitis obliterans, diffuse bronchiolitis; patients with pulmonary embolism, pneumothorax, pleural effusion; (7) neuromuscular diseases that affect respiratory function; (8) severe liver and kidney disease, such as cirrhosis, portal hypertension and variceal bleeding; dialysis, kidney transplantation; (9) long-term bedridden patients; (10) within 1 month prior to oral administration of glucocorticoid; (11) congenital or acquired immunodeficiency syndrome; (12) are participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
AECOPD;

Secondary

MeasureTime frame
Pulmonary function test;Quality of life;Effectiveness satisfaction questionnaire;

Countries

China

Contacts

Public ContactLiping Guo

Tianjin University of Traditional Chinese Medicine

lpgtjn@163.com+86 13821806546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026